guest ::
| Home > Publications database > Chemoradiation in female patients with anal cancer: Patient-reported outcome of acute and chronic side effects. > print |
| Home > Publications database > Chemoradiation in female patients with anal cancer: Patient-reported outcome of acute and chronic side effects. > print |
| 001 | 141816 | ||
| 005 | 20240229112527.0 | ||
| 024 | 7 | _ | |a 10.1177/0300891618811273 |2 doi |
| 024 | 7 | _ | |a pmid:30484384 |2 pmid |
| 024 | 7 | _ | |a 0300-8916 |2 ISSN |
| 024 | 7 | _ | |a 2038-2529 |2 ISSN |
| 024 | 7 | _ | |a altmetric:93531706 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2018-02084 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Koerber, Stefan A |b 0 |
| 245 | _ | _ | |a Chemoradiation in female patients with anal cancer: Patient-reported outcome of acute and chronic side effects. |
| 260 | _ | _ | |a Thousand Oaks, Calif. |c 2019 |b Sage |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1555317996_7657 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a We evaluated acute and chronic side effects of 3D conformal radiotherapy (3D-CRT) and intensity-modulated radiation therapy (IMRT) in female patients with anal carcinoma and accessed correlations between dosimetric parameters and the considered toxicities.For 70 women with anal cancer treated at our department, acute and chronic side effects and quality of life (QoL) were evaluated with questionnaires using the Common Terminology Criteria for Adverse Events (CTCAE v. 4.0.) and Late Effects in Normal Tissue, Subjective, Objective Management and Analytic Scales (LentSoma) before, during, and after the treatment.Forty-seven out of 70 (67%) patients completed the questionnaire and were enrolled in the study. Only poor urinary stream, loss of pubic hair during chemoradiation, and chronic vaginal dryness were observed more frequently in the 3D-CRT group compared to the IMRT group (univariable logistic regression p = .032, p = .04, p = .049, respectively). After the treatment, 43% in the 3D-CRT group and 29% in the IMRT group reported a severe loss of QoL. A higher proportion among the patients receiving a genital V20 ⩾35% showed grade 1-3 side effects such as chronic dyspareunia ( p = .035; Fisher exact test).Our results suggest that the use of IMRT decreases acute and chronic adverse effects although reduced QoL also occurred in the IMRT group. These effects are likely to be underreported in retrospective studies using physician-reported outcome measures. |
| 536 | _ | _ | |a 313 - Cancer risk factors and prevention (POF3-313) |0 G:(DE-HGF)POF3-313 |c POF3-313 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 700 | 1 | _ | |a Seither, Ben |b 1 |
| 700 | 1 | _ | |a Slynko, Alla |0 P:(DE-He78)4169c43af2de6fae487c89fc2e7cfaa8 |b 2 |u dkfz |
| 700 | 1 | _ | |a Haefner, Matthias F |b 3 |
| 700 | 1 | _ | |a Krug, David |b 4 |
| 700 | 1 | _ | |a Liermann, Jakob |b 5 |
| 700 | 1 | _ | |a Adeberg, Sebastian |b 6 |
| 700 | 1 | _ | |a Herfarth, Klaus |b 7 |
| 700 | 1 | _ | |a Debus, Juergen |b 8 |
| 700 | 1 | _ | |a Sterzing, Florian |b 9 |
| 773 | _ | _ | |a 10.1177/0300891618811273 |g p. 030089161881127 - |0 PERI:(DE-600)2267832-3 |n 2 |p 174-180 |t Tumori journal |v 105 |y 2019 |x 2038-2529 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:141816 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)4169c43af2de6fae487c89fc2e7cfaa8 |
| 913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-313 |2 G:(DE-HGF)POF3-300 |v Cancer risk factors and prevention |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
| 914 | 1 | _ | |y 2019 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b TUMORI J : 2017 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |
| 920 | 1 | _ | |0 I:(DE-He78)C060-20160331 |k C060 |l Biostatistik |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C060-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|